News

The good news for the younger generations is that boomers are already showering some of their money on their heirs.

Nvidia has posted eight straight quarters of revenue growth while Navitas Semiconductor faces a downward spiral, widening the gap between the two chipmakers.

The disposition reduced the insider's total equity holdings by 10%.

Two semiconductor ETFs hold nearly identical stocks, yet one has left the other in the dust this year by a staggering margin. The difference has nothing to do with which chips are inside and everything to do with how the fund is built.

A concerning historical pattern likely has weighed on Micron stock.

Investor and television personality Kevin O’Leary said the U.S. economy is showing strength through strong corporate earnings and stock market gains, but warned that persistent inflation and high energy costs are preventing many Americans from feeling the benefits. O’Leary Warns...

Here's how investors should prepare for potential volatility.

This non-discretionary sale was tied to equity vesting tax obligations.

Innodata stock has delivered very strong returns over the past five years, yet the broader valuation checks suggest it no longer looks like a clear bargain. After such a strong run and with fresh AI related product news, the current share price raises questions about how much good news is already reflected. Innodata has returned about 7x over five years, which puts extra focus on whether the current price still leaves room for attractive long term returns. New AI focused offerings such as...

Why Red Cat Holdings Stock Is Back in Focus Red Cat Holdings (RCAT) is back on investor watchlists after reporting very large year over year revenue growth in Q2 2026, reaffirming full year revenue guidance, and highlighting progress across its autonomy platforms. The latest update links strong top line growth with broader international demand, a less concentrated customer base that now includes Japan and NATO, and advancement in aerial drones and maritime systems such as the Variant 7...

TJX Companies stock has delivered strong long term returns over the past five years, yet the current market multiples and valuation checks suggest the shares are pricing in a full outlook rather than offering a clear bargain. Over the past 5 years, TJX Companies has returned 145.3%, which puts extra focus on whether the current share price already reflects much of that success. Future revenue and cash flow expectations for TJX Companies can support today’s valuation, while any pressure on...

Advanced Micro Devices (AMD) has spent 2026 proving it can compete with Nvidia in the artificial intelligence race. Its stock has more than doubled this year, and its data center business is growing fast. Now AMD is trying something different. The company just bought a small Toronto startup ...

What does $12 billion of market value buy when combined sales run about $12 million?

Blue Owl Capital (NYSE:OBDC) reported second-quarter 2026 adjusted net investment income of $0.34 per share, up from $0.31 in the prior quarter, as a large investment realization and higher specialty-finance dividend income lifted results. Net asset value per share declined to $14.26 from $14.41 in

Realty Income (NYSE:O) raised its full-year 2026 outlook after reporting second-quarter adjusted funds from operations, or AFFO, per share growth of 3.8% to $1.09, supported by investment activity across industrial properties, Europe, private-capital vehicles and data centers. Year-to-date AFFO per

NexGen Energy (NYSE:NXE) said construction activities at its Rook I uranium project in Saskatchewan advanced on schedule and within budget during the second quarter of 2026, as the company continued to pursue uranium sales agreements and evaluate financing options for the project’s remaining constru

Novo Nordisk A/S (NYSE:NVO) reported second-quarter adjusted sales growth of 7% at constant exchange rates, supported by GLP-1 volume growth across its obesity and diabetes franchises, while lower realized prices and manufacturing-related costs weighed on margins. Chief Executive Officer Mike Doust

Non-discretionary vesting event reduces his direct holdings by 4%, yet Stewart maintains a $4.89 million equity stake in the semiconductor firm.

Hedge fund Situational Awareness is forced to sell its equity holdings, leading to a drop and a pop in AI-related stocks. What went wrong?

This insider retains 124,261 shares worth $11.84 million after non-discretionary equity vesting.

The home improvement giant has significantly underperformed its bigger retail peer in the past five years.

Replicating a Social Security check with dividends sounds straightforward until you realize the yield you chase determines whether your income grows, stalls, or quietly disappears over the next two decades.

This insider retains 79,460 shares worth about $7.6 million after non-discretionary equity vesting disposition.

New York City Mayor Zohran Kwame Mamdani has launched a crackdown on online retailers selling allegedly illegal high-speed e-bikes and e-scooters, targeting major platforms including Walmart Inc., Target Corp., Wayfair Inc., Temu parent PDD Holdings Inc and Amazon.com, Inc. over...

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 47.7% year on year to $22.97 billion. The company’s full-year revenue guidance of $86 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $8.38 per share was 27.3% above analysts’ consensus estimates.

The CFO of Qorvo retains 54,447 shares valued at $5.2 million.

They are going through a rough patch, but it's too early to give up on them.

The CEO of Qorvo maintains roughly 354,000 shares directly held post-transaction, signaling continued confidence despite routine liquidity needs.

Eli Lilly (NYSE: LLY) reported that its KRAS G12C inhibitor olomorasib received FDA Breakthrough Therapy designation for advanced pancreatic cancer in patients with a KRAS G12C mutation. The company entered a new clinical trial collaboration with Amplia Therapeutics to test olomorasib in combination with Amplia's FAK inhibitor narmafotinib in advanced non small cell lung cancer. These developments highlight Eli Lilly's efforts to broaden its oncology portfolio beyond its diabetes and obesity...

Doximity, Inc. recently reported fiscal first-quarter 2027 results, with revenue rising to US$156.62 million from US$145.91 million a year earlier, while net income and earnings per share declined year on year. Management emphasized rapid uptake and monetization of its clinical AI tools, updating guidance to US$170–171 million for second-quarter revenue and US$671–681 million for full-year revenue. We’ll now examine how Doximity’s raised revenue outlook, underpinned by accelerating adoption...